|
1
|
Vaidya A, Soloway MS, Hawke C, Tiguert R
and Civantos F: De novo muscle invasive bladder cancer: Is there a
change in trend? J Urol. 165:47–50. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stein JP, Lieskovsky G, Cote R, Groshen S,
Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M,
et al: Radical cystectomy in the treatment of invasive bladder
cancer: Long-term results in 1,054 patients. J Clin Oncol.
19:666–675. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sternberg CN, Yagoda A, Scher HI, Watson
RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani
PC, et al: Preliminary results of M-VAC (methotrexate, vinblastine,
doxorubicin and cisplatin) for transitional cell carcinoma of the
urothelium. J Urol. 133:403–407. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Loehrer PJ Sr, Einhorn LH, Elson PJ,
Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R,
Sarosdy MF, Lowe BA, et al: A randomized comparison of cisplatin
alone or in combination with methotrexate, vinblastine and
doxorubicin in patients with metastatic urothelial carcinoma: A
cooperative group study. J Clin Oncol. 10:1066–1073. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sternberg CN, Yagoda A, Scher HI, Watson
RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N,
et al: Methotrexate, vinblastine, doxorubicin, and cisplatin for
advanced transitional cell carcinoma of the urothelium. Efficacy
and patterns of response and relapse. Cancer. 64:2448–2458. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sternberg CN, Yagoda A, Scher HI, Watson
RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED Jr, Bander N,
Weiselberg LR, et al: M-VAC (methotrexate, vinblastine, doxorubicin
and cisplatin) for advanced transitional cell carcinoma of the
urothelium. J Urol. 139:461–469. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Saxman SB, Propert KJ, Einhorn LH,
Crawford ED, Tannock I, Raghavan D, Loehrer PJ Sr and Trump D:
Long-term follow-up of a phase III intergroup study of cisplatin
alone or in combination with methotrexate, vinblastine, and
doxorubicin in patients with metastatic urothelial carcinoma: A
cooperative group study. J Clin Oncol. 15:2564–2569. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
von der Maase H, Hansen SW, Roberts JT,
Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A,
Lippert CM, et al: Gemcitabine and cisplatin versus methotrexate,
vinblastine, doxorubicin, and cisplatin in advanced or metastatic
bladder cancer: Results of a large, randomized, multinational,
multicenter, phase III study. J Clin Oncol. 18:3068–3077. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bellmunt J, Théodore C, Demkov T, Komyakov
B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A,
Karyakin O, et al: Phase III trial of vinflunine plus best
supportive care compared with best supportive care alone after a
platinum-containing regimen in patients with advanced transitional
cell carcinoma of the urothelial tract. J Clin Oncol. 27:4454–4461.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vaishampayan UN, Faulkner JR, Small EJ,
Redman BG, Keiser WL, Petrylak DP and Crawford ED: Phase II trial
of carboplatin and paclitaxel in cisplatin-pretreated advanced
transitional cell carcinoma: A Southwest Oncology Group study.
Cancer. 104:1627–1632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Soga N, Onishi T, Arima K and Sugimura Y:
Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy
for advanced platinum resistant urothelial cancer in Japanese
cases. Int J Urol. 14:828–832. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kouno T, Ando M, Yonemori K, Matsumoto K,
Shimizu C, Katsumata N, Komiyama M, Okajima E, Matsuoka N, Fujimoto
H and Fujiwara Y: Weekly paclitaxel and carboplatin against
advanced transitional cell cancer after failure of a platinum-based
regimen. Eur Urol. 52:1115–1122. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
|
|
14
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
von der Maase H, Sengelov L, Roberts JT,
Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning
M: Long-term survival results of a randomized trial comparing
gemcitabine plus cisplatin, with methotrexate, vinblastine,
doxorubicin, plus cisplatin in patients with bladder cancer. J Clin
Oncol. 23:4602–4608. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lorusso V, Pollera CF, Antimi M, Luporini
G, Gridelli C, Frassineti GL, Oliva C, Pacini M and De Lena M: A
phase II study of gemcitabine in patients with transitional cell
carcinoma of the urinary tract previously treated with platinum.
Italian Co-operative Group on Bladder Cancer. Eur J Cancer.
34:1208–1212. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
McCaffrey JA, Hilton S, Mazumdar M, Sadan
S, Kelly WK, Scher HI and Bajorin DF: Phase II trial of docetaxel
in patients with advanced or metastatic transitional-cell
carcinoma. J Clin Oncol. 15:1853–1857. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Papamichael D, Gallagher CJ, Oliver RT,
Johnson PW and Waxman J: Phase II study of paclitaxel in pretreated
patients with locally advanced/metastatic cancer of the bladder and
ureter. Br J Cancer. 75:606–607. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vaughn DJ, Broome CM, Hussain M, Gutheil
JC and Markowitz AB: Phase II trial of weekly paclitaxel in
patients with previously treated advanced urothelial cancer. J Clin
Oncol. 20:937–940. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn
DJ, Arning M, Curiel RE, Obasaju CK, Wang Y, Nicol SJ and Kaufman
DS: Phase II study of pemetrexed for second-line treatment of
transitional cell cancer of the urothelium. J Clin Oncol.
24:3451–3457. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Galsky MD, Mironov S, Iasonos A,
Scattergood J, Boyle MG and Bajorin DF: Phase II trial of
pemetrexed as second-line therapy in patients with metastatic
urothelial carcinoma. Invest New Drugs. 25:265–270. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Witte RS, Elson P, Bono B, Knop R,
Richardson RR, Dreicer R and Loehrer PJ Sr: Eastern Cooperative
Oncology Group phase II trial of ifosfamide in the treatment of
previously treated advanced urothelial carcinoma. J Clin Oncol.
15:589–593. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Han KS, Joung JY, Kim TS, Jeong IG, Seo
HK, Chung J and Lee KH: Methotrexate, vinblastine, doxorubicin and
cisplatin combination regimen as salvage chemotherapy for patients
with advanced or metastatic transitional cell carcinoma after
failure of gemcitabine and cisplatin chemotherapy. Br J Cancer.
98:86–90. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
National Comprehensive Cancer Network:
Guidelines on bladder cancer. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf/December
1–2016
|
|
25
|
Roth BJ, Dreicer R, Einhorn LH, Neuberg D,
Johnson DH, Smith JL, Hudes GR, Schultz SM and Loehrer PJ:
Significant activity of paclitaxel in advanced transitional-cell
carcinoma of the urothelium: A phase II trial of the Eastern
Cooperative Oncology Group. J Clin Oncol. 12:2264–2270. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Burch PA, Richardson RL, Cha SS, Sargent
DJ, Pitot HC IV, Kaur JS and Camoriano JK: Phase II study of
paclitaxel and cisplatin for advanced urothelial cancer. J Urol.
164:1538–1542. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pagliaro LC, Millikan RE, Tu SM, Williams
D, Daliani D, Papandreou CN and Logothetis CJ: Cisplatin,
gemcitabine and ifosfamide as weekly therapy: A feasibility and
phase II study of salvage treatment for advanced transitional-cell
carcinoma. J Clin Oncol. 20:2965–2970. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Esteban-Fernández D, Verdaguer JM,
Ramírez-Camacho R, Palacios MA and Gómez-Gómez MM: Accumulation,
fractionation and analysis of platinum in toxicologically affected
tissues after cisplatin, oxaliplatin and carboplatin
administration. J Anal Toxicol. 32:140–146. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Albers P, Park SI, Niegisch G, Fechner G,
Steiner U, Lehmann J, Heimbach D, Heidenreich A, Fimmers R and
Siener R: AUO Bladder Cancer Group: Randomized phase III trial of
2nd line gemcitabine and paclitaxel chemotherapy in patients with
advanced bladder cancer: Short-term versus prolonged treatment
[German Association of Urological Oncology (AUO) trial AB 20/99].
Ann Oncol. 22:288–294. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pond GR, Bellmunt J, Fougeray R, Choueiri
TK, Qu AQ, Niegisch G, Albers P, Di Lorenzo G, Salhi Y, Galsky MD,
et al: Impact of response to prior chemotherapy in patients with
advanced urothelial carcinoma receiving second-line therapy:
Implications for trial design. Clin Genitourin Cancer. 11:495–500.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bellmunt J, Choueiri TK, Fougeray R,
Schutz FA, Salhi Y, Winquist E, Culine S, von der Maase H, Vaughn
DJ and Rosenberg JE: Prognostic factors in patients with advanced
transitional cell carcinoma of the urothelial tract experiencing
treatment failure with platinum-containing regimens. J Clin Oncol.
28:1850–1855. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Niegisch G, Fimmers R, Siener R, Park SI
and Albers P: German Association of Urological Oncology Bladder
Cancer Group: Prognostic factors in second-line treatment of
urothelial cancers with gemcitabine and paclitaxel (German
Association of Urological Oncology trial AB20/99). Eur Urol.
60:1087–1096. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ikeda M, Matsumoto K, Tabata K, Minamida
S, Fujita T, Satoh T, Iwamura M and Baba S: Combination of
gemcitabine and paclitaxel is a favorable option for patients with
advanced or metastatic urothelial carcinoma previously treated with
cisplatin-based chemotherapy. Jpn J Clin Oncol. 41:1214–1220. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee JL, Ahn JH, Park SH, Lim HY, Kwon JH,
Ahn S, Song C, Hong JH, Kim CS and Ahn H: Phase II study of a
cremophor-free, polymeric micelle formulation of paclitaxel for
patients with advanced urothelial cancer previously treated with
gemcitabine and platinum. Invest New Drugs. 30:1984–1990. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Krajewski KM, Fougeray R, Bellmunt J, Pons
F, Schutz FA, Rosenberg JE, Salhi Y and Choueiri TK: Optimisation
of the size variation threshold for imaging evaluation of response
in patients with platinum-refractory advanced transitional cell
carcinoma of the urothelium treated with vinflunine. Eur J Cancer.
48:1495–1502. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Choueiri TK, Ross RW, Jacobus S,
Vaishampayan U, Yu EY, Quinn DI, Hahn NM, Hutson TE, Sonpavde G,
Morrissey SC, et al: Double-blind, randomized trial of docetaxel
plus vandetanib versus docetaxel plus placebo in
platinum-pretreated metastatic urothelial cancer. J Clin Oncol.
30:507–512. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ko YJ, Canil CM, Mukherjee SD, Winquist E,
Elser C, Eisen A, Reaume MN, Zhang L and Sridhar SS: Nanoparticle
albumin-bound paclitaxel for second-line treatment of metastatic
urothelial carcinoma: A single group, multicentre, phase 2 study.
Lancet Oncol. 14:769–776. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Buti S, Ciccarese C, Zanoni D, Santoni M,
Modena A, Maines F, Gilli A, Bria E, Brunelli M, Rimanti A, et al:
Prognostic and predictive factors in patients treated with
chemotherapy for advanced urothelial cancer: Where do we stand?
Future Oncol. 11:107–119. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Terakawa T, Miyake H, Yokoyama N, Miyazaki
A, Tanaka H, Inoue T and Fujisawa M: Clinical outcome of paclitaxel
and carboplatin as second-line chemotherapy for advanced urothelial
carcinoma resistant to first-line therapy with gemcitabine and
cisplatin. Urol Int. 92:180–185. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Weinstock M and McDermott D: Targeting
PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma.
Ther Adv Urol. 7:365–377. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hamid O, Robert C, Daud A, Hodi FS, Hwu
WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al:
Safety and tumor responses with lambrolizumab (anti-PD-1) in
melanoma. N Engl J Med. 369:134–144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Powles T, Eder JP, Fine GD, Braiteh FS,
Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, et
al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in
metastatic bladder cancer. Nature. 515:558–562. 2014. View Article : Google Scholar : PubMed/NCBI
|
